Deciphering the Multifaceted Relationship Between Oncolytic Viruses and Natural Killer Cells

Overview

Journal Adv Virol

Publisher Wiley

Specialty Microbiology

Date 2012 Feb 8

PMID 22312364

Citations 13

Authors

Christopher A Alvarez-Breckenridge

Jianhua Yu

Balveen Kaur

Michael A Caligiuri

E Antonio Chiocca

Affiliations

Soon will be listed here.

Abstract

Despite active research in virotherapy, this apparently safe modality has not achieved widespread success. The immune response to viral infection appears to be an essential factor that determines the efficacy of oncolytic viral therapy. The challenge is determining whether the viral-elicited immune response is a hindrance or a tool for viral treatment. NK cells are a key component of innate immunity that mediates antiviral immunity while also coordinating tumor clearance. Various reports have suggested that the NK response to oncolytic viral therapy is a critical factor in premature viral clearance while also mediating downstream antitumor immunity. As a result, particular attention should be given to the NK cell response to various oncolytic viral vectors and how their antiviral properties can be suppressed while maintaining tumor clearance. In this review we discuss the current literature on the NK response to oncolytic viral infection and how future studies clarify this intricate response.

Citing Articles

Oncolytic virotherapy augments self-maintaining natural killer cell line cytotoxicity against neuroblastoma.

Quinn C, Julson J, Markert H, Nazam N, Butey S, Stewart J Cancer Immunol Immunother. 2024; 73(11):221.

PMID: 39235531 PMC: 11377387. DOI: 10.1007/s00262-024-03818-y.

Strategies to Optimise Oncolytic Viral Therapies: The Role of Natural Killer Cells.

Leung E, McNeish I Viruses. 2021; 13(8).

PMID: 34452316 PMC: 8402671. DOI: 10.3390/v13081450.

Transfer learning between preclinical models and human tumors identifies a conserved NK cell activation signature in anti-CTLA-4 responsive tumors.

Davis-Marcisak E, Fitzgerald A, Kessler M, Danilova L, Jaffee E, Zaidi N Genome Med. 2021; 13(1):129.

PMID: 34376232 PMC: 8356429. DOI: 10.1186/s13073-021-00944-5.

Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy.

Shin D, Nguyen T, Ozpolat B, Lang F, Alonso M, Gomez-Manzano C J Immunother Cancer. 2021; 9(4).

PMID: 33795384 PMC: 8021759. DOI: 10.1136/jitc-2020-002086.

Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs.

Braidwood L, Graham S, Graham A, Conner J Oncolytic Virother. 2016; 2:57-74.

PMID: 27512658 PMC: 4918355. DOI: 10.2147/OV.S52601.

References

Gousias K, Markou M, Arzoglou V, Voulgaris S, Vartholomatos G, Kostoula A . Frequent abnormalities of the immune system in gliomas and correlation with the WHO grading system of malignancy. J Neuroimmunol. 2010; 226(1-2):136-42. DOI: 10.1016/j.jneuroim.2010.05.027. View

Schepis D, Damato M, Studahl M, Bergstrom T, Karre K, Berg L . Herpes simplex virus infection downmodulates NKG2D ligand expression. Scand J Immunol. 2009; 69(5):429-36. DOI: 10.1111/j.1365-3083.2009.02241.x. View

Garber K . China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst. 2006; 98(5):298-300. DOI: 10.1093/jnci/djj111. View

Pogge von Strandmann E, Simhadri V, von Tresckow B, Sasse S, Reiners K, Hansen H . Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity. 2007; 27(6):965-74. DOI: 10.1016/j.immuni.2007.10.010. View

Li H, Zeng Z, Fu X, Zhang X . Coadministration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses. Cancer Res. 2007; 67(16):7850-5. DOI: 10.1158/0008-5472.CAN-07-1087. View

Martuza R, Malick A, Markert J, Ruffner K, Coen D . Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991; 252(5007):854-6. DOI: 10.1126/science.1851332. View

Rosenberg S, Mule J, Spiess P, Reichert C, Schwarz S . Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med. 1985; 161(5):1169-88. PMC: 2187617. DOI: 10.1084/jem.161.5.1169. View

Esendagli G, Bruderek K, Goldmann T, Busche A, Branscheid D, Vollmer E . Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer. Lung Cancer. 2007; 59(1):32-40. DOI: 10.1016/j.lungcan.2007.07.022. View

Kishimoto T, Hollander N, Roberts T, Anderson D, Springer T . Heterogeneous mutations in the beta subunit common to the LFA-1, Mac-1, and p150,95 glycoproteins cause leukocyte adhesion deficiency. Cell. 1987; 50(2):193-202. DOI: 10.1016/0092-8674(87)90215-7. View

10.

Fulci G, Dmitrieva N, Gianni D, Fontana E, Pan X, Lu Y . Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res. 2007; 67(19):9398-406. PMC: 2850558. DOI: 10.1158/0008-5472.CAN-07-1063. View

11.

Hickey W . Leukocyte traffic in the central nervous system: the participants and their roles. Semin Immunol. 1999; 11(2):125-37. DOI: 10.1006/smim.1999.0168. View

12.

Ikeda K, Ichikawa T, Wakimoto H, Silver J, Deisboeck T, Finkelstein D . Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med. 1999; 5(8):881-7. DOI: 10.1038/11320. View

13.

Trotta R, Dal Col J, Yu J, Ciarlariello D, Thomas B, Zhang X . TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol. 2008; 181(6):3784-92. PMC: 2924753. DOI: 10.4049/jimmunol.181.6.3784. View

14.

Altomonte J, Wu L, Chen L, Meseck M, Ebert O, Garcia-Sastre A . Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo. Mol Ther. 2007; 16(1):146-53. PMC: 2930752. DOI: 10.1038/sj.mt.6300343. View

15.

Jawahar S, Moody C, Chan M, Finberg R, Geha R, Chatila T . Natural Killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II). Clin Exp Immunol. 1996; 103(3):408-13. PMC: 2200361. DOI: 10.1111/j.1365-2249.1996.tb08295.x. View

16.

Qiao J, Wang H, Kottke T, White C, Twigger K, Diaz R . Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res. 2008; 14(1):259-69. PMC: 3046731. DOI: 10.1158/1078-0432.CCR-07-1510. View

17.

Alvarez-Breckenridge C, Kaur B, Chiocca E . Pharmacologic and chemical adjuvants in tumor virotherapy. Chem Rev. 2009; 109(7):3125-40. PMC: 2790404. DOI: 10.1021/cr900048k. View

18.

Kottke T, Galivo F, Wongthida P, Diaz R, Thompson J, Jevremovic D . Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Mol Ther. 2008; 16(7):1217-26. PMC: 2729455. DOI: 10.1038/mt.2008.83. View

19.

Waldhauer I, Steinle A . NK cells and cancer immunosurveillance. Oncogene. 2008; 27(45):5932-43. DOI: 10.1038/onc.2008.267. View

20.

Biron C, Nguyen K, Pien G, Cousens L, Salazar-Mather T . Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol. 1999; 17:189-220. DOI: 10.1146/annurev.immunol.17.1.189. View